Vivesto (OM:VIVE) - Share price, News & Analysis

VIVE fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

VIVE Stock Overview

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden.

Rewards

Revenue is forecast to grow 60.29% per year

Risk Analysis

Earnings have declined by 10.6% per year over past 5 years

Has less than 1 year of cash runway

Shareholders have been diluted in the past year

Does not have meaningful revenue (SEK29M)

+ 1 more risk

Vivesto Competitors

Saniona

OM:SANION

kr274.2m

Alligator Bioscience

OM:ATORX

kr408.1m

Egetis Therapeutics

OM:EGTX

kr802.6m

Medivir

OM:MVIR B

kr451.4m

Price History & Performance

Summary of all time highs, changes and price drops for Vivesto
Historical stock prices
Current Share Price	kr0.78
52 Week High	kr3.03
52 Week Low	kr0.57
Beta	0.58
1 Month Change	14.12%
3 Month Change	-30.09%
1 Year Change	-73.41%
3 Year Change	-85.05%
5 Year Change	-73.43%
Change since IPO	-97.03%

Shareholder Returns

	VIVE	SE Biotechs	SE Market
7D	10.9%	-1.9%	-0.8%
1Y	-73.4%	-22.8%	-23.9%

Return vs Industry: VIVE underperformed the Swedish Biotechs industry which returned -22.1% over the past year.

Return vs Market: VIVE underperformed the Swedish Market which returned -22% over the past year.

Price Volatility

Is VIVE's price volatile compared to industry and market?
VIVE volatility
VIVE Average Weekly Movement	8.7%
Biotechs Industry Average Movement	9.7%
Market Average Movement	7.3%
10% most volatile stocks in SE Market	12.7%
10% least volatile stocks in SE Market	4.6%

Stable Share Price: VIVE is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: VIVE's weekly volatility (9%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1988	19	Christer Nordstedt	https://www.vivesto.com

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company’s products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer.

Vivesto Fundamentals Summary

How do Vivesto's earnings and revenue compare to its market cap?
VIVE fundamental statistics
Market Cap	kr417.52m
Earnings (TTM)	-kr117.97m
Revenue (TTM)	kr28.83m

14.5x

P/S Ratio

-3.5x

P/E Ratio

Is VIVE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
VIVE income statement (TTM)
Revenue	kr28.83m
Cost of Revenue	kr44.09m
Gross Profit	-kr15.26m
Other Expenses	kr102.71m
Earnings	-kr117.97m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 25, 2022

Earnings per share (EPS)	-0.22
Gross Margin	-52.94%
Net Profit Margin	-409.18%
Debt/Equity Ratio	0%

How did VIVE perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is VIVE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VIVE?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for VIVE. This is calculated by dividing VIVE's market cap by their current preferred multiple.
What is VIVE's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	kr417.52m

VIVE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	12.2x
Enterprise Value/EBITDA	-3.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does VIVE's PS Ratio compare to its peers?

VIVE PS Ratio vs Peers

The above table shows the PS ratio for VIVE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PS	Estimated Growth	Market Cap
Peer Average	22.1x
SANION Saniona	20.1x	n/a	kr274.2m
ATORX Alligator Bioscience	20.8x	101.6%	kr408.1m
EGTX Egetis Therapeutics	19.3x	77.3%	kr802.6m
MVIR B Medivir	28.4x	76.6%	kr451.4m
VIVE Vivesto	14.5x	60.3%	kr417.5m

Price-To-Sales vs Peers: VIVE is good value based on its Price-To-Sales Ratio (14.5x) compared to the peer average (22.1x).

Price to Earnings Ratio vs Industry

How does VIVE's PE Ratio compare vs other companies in the SE Biotechs Industry?

Price-To-Sales vs Industry: VIVE is good value based on its Price-To-Sales Ratio (14.5x) compared to the Swedish Biotechs industry average (24.5x)

Price to Sales Ratio vs Fair Ratio

What is VIVE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VIVE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	14.5x
Fair PS Ratio	6.7x

Price-To-Sales vs Fair Ratio: VIVE is expensive based on its Price-To-Sales Ratio (14.5x) compared to the estimated Fair Price-To-Sales Ratio (6.7x).

Share Price vs Fair Value

What is the Fair Price of VIVE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VIVE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VIVE's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Vivesto forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

60.3%

Forecasted annual revenue growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if VIVE's forecast earnings growth is above the savings rate (0.4%).

Earnings vs Market: Insufficient data to determine if VIVE's earnings are forecast to grow faster than the Swedish market

High Growth Earnings: Insufficient data to determine if VIVE's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: VIVE's revenue (60.3% per year) is forecast to grow faster than the Swedish market (11% per year).

High Growth Revenue: VIVE's revenue (60.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if VIVE's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has Vivesto performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-10.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: VIVE is currently unprofitable.

Growing Profit Margin: VIVE is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: VIVE is unprofitable, and losses have increased over the past 5 years at a rate of 10.6% per year.

Accelerating Growth: Unable to compare VIVE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VIVE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.2%).

Return on Equity

High ROE: VIVE has a negative Return on Equity (-17.93%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Vivesto's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: VIVE's short term assets (SEK250.8M) exceed its short term liabilities (SEK39.4M).

Long Term Liabilities: VIVE's short term assets (SEK250.8M) exceed its long term liabilities (SEK4.3M).

Debt to Equity History and Analysis

Debt Level: VIVE is debt free.

Reducing Debt: VIVE has no debt compared to 5 years ago when its debt to equity ratio was 55.6%.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VIVE has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: VIVE has less than a year of cash runway if free cash flow continues to reduce at historical rates of 7.3% each year

Discover healthy companies

Dividend

What is Vivesto current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate VIVE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VIVE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VIVE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VIVE's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as VIVE has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure

CEO

Christer Nordstedt (60 yo)

0.083

Tenure

Dr. Christer Nordstedt, M.D., Ph D., serves as Acting Chief Executive Officer at Vivesto AB since July 21, 2022. He serves as Chairman of the Board at WntResearch AB since 2022.He is engaged as a consulta...

Leadership Team

Experienced Management: VIVE's management team is considered experienced (2.6 years average tenure).

Board Members

Experienced Board: VIVE's board of directors are considered experienced (3.1 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20%.

Data	Last Updated (UTC time)
Company Analysis	2022/08/09 00:00
End of Day Share Price	2022/08/09 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31